Palomino Laboratories Inc. entered into subscription agreements for a private placement of its common stock. On April 20, 2026, the company sold 3,773,853 shares at $4.00 per share, raising $15,095,412 in an initial closing, with the Offering permitted to reach up to $30,000,000 through additional closings by April 30, 2026.
Laidlaw & Company (UK) Ltd. will receive cash fees and expense reimbursements based on gross proceeds, plus warrants equal to 10% of shares sold to its introduced investors at a 120% exercise price. Investors received registration rights requiring Palomino to file resale registration statements and provide piggyback rights, giving a pathway to eventual public resale of the privately placed shares.
Palomino Laboratories Inc. director and secretary Richard Ogawa made an open-market purchase of the company’s Common Stock. He bought 12,500 shares at $4.00 per share, increasing his direct holdings to 1,762,500 shares. This filing shows a modest increase in his personal investment stake.
Palomino Laboratories Inc. director Steven Denbaars made an open-market purchase of 12,500 shares of Common Stock at $4.00 per share on April 20, 2026. After this transaction, he directly owns 1,762,500 shares of the company’s Common Stock.